| P2093 | author name string | Michael E Thase | |
| P2860 | cites work | A 3-year follow-up of a group of treatment-resistant depressed patients with a MAOI/tricyclic combination. | Q54008158 |
| | Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. | Q54195565 |
| | Combining Antidepressants for Treatment-Resistant Depression | Q56038603 |
| | Tranylcypromine Versus Venlafaxine Plus Mirtazapine Following Three Failed Antidepressant Medication Trials for Depression: A STAR*D Report | Q57616045 |
| | Polypharmacy: when is it rational? | Q80112030 |
| | Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression | Q33597603 |
| | Medication augmentation after the failure of SSRIs for depression. | Q33994373 |
| | SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability | Q34066581 |
| | Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. | Q34088016 |
| | National trends in psychotropic medication polypharmacy in office-based psychiatry | Q34090959 |
| | Bupropion occupancy of the dopamine transporter is low during clinical treatment. | Q34145068 |
| | Combining antidepressants for treatment-resistant depression: a review | Q34146187 |
| | In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography | Q34269010 |
| | Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. | Q34562454 |
| | Multi-modality: a new approach for the treatment of major depressive disorder | Q36896252 |
| | Antidepressant combinations: widely used, but far from empirically validated | Q37901099 |
| | MAOIs in the contemporary treatment of depression | Q40444762 |
| | A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression | Q41180795 |
| | Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression | Q42625289 |
| | Combining antidepressant medications: a good idea? | Q43145658 |
| | A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine | Q43873749 |
| | Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. | Q44097670 |
| | Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study | Q44742910 |
| | Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation | Q46062036 |
| | Lack of efficacy of L-759274, a novel neurokinin 1 (substance P) receptor antagonist, for the treatment of generalized anxiety disorder. | Q48000888 |
| | Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial | Q48547842 |
| | Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. | Q48878233 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 403 | |
| P577 | publication date | 2013-10-01 | |
| P1433 | published in | Current Psychiatry Reports | Q25245507 |
| P1476 | title | Antidepressant combinations: cutting edge psychopharmacology or passing fad? | |
| P478 | volume | 15 | |